1. Synthesis, modeling and biological evaluation of some pyrazolo[3,4-d]pyrimidinones and pyrazolo[4,3-e][1,2,4]triazolo[4,3-a]pyrimidinones as anti-inflammatory agents.
- Author
-
Tageldin, Gina N., Ibrahim, Tamer M., Fahmy, Salwa M., Ashour, Hayam M., Khalil, Mounir A., Nassra, Rasha A., and Labouta, Ibrahim M.
- Subjects
- *
ANTI-inflammatory agents , *BIOLOGICAL models , *PYRIMIDINES , *MOLECULAR docking , *IN vivo studies , *FOOT - Abstract
• New pyrazolo[3,4-d]pyrimidines and pyrazolo[4,3-e][1,2,4]triazolo[4,3-a]pyrimidines were designed and synthesized. • In vitro COX-1/COX-2 inhibitory assay. • In vivo formalin paw edema and cotton pellets induced granuloma assays. • Docking experiments rationalized in vitro COX-2 inhibitory activity. • In silico pharmacokinetics and drug-likeness predictions recommended acceptable profiles. New pyrazolo[3,4- d ]pyrimidinone and pyrazolo[4,3-e][1,2,4]triazolo[4,3- a ]pyrimidinone derivatives were synthesized. They have been evaluated for their anti-inflammatory activity using in vitro (COX-1/COX-2) inhibitory assay. Moreover, compounds with promising in vitro activity and COX-1/COX-2 selectivity indices were subjected for in vivo anti-inflammatory testing using formalin induced paw edema and cotton-pellet induced granuloma assays for acute and chronic models, respectively. Compounds (2c, 3i, 6a, 8 and 12) showed promising COX-2 inhibitory activity and high selectivity compared to celecoxib. Most of the compounds exhibited potential anti-inflammatory activity for both in vivo acute and chronic models. Almost all compounds displayed safe gastrointestinal profile and low ulcerogenic potential guided by histopathological examination. Furthermore, molecular docking experiments rationalized the observed i n vitro anti-inflammatory activity of selected candidates. In silico predictions of the pharmacokinetic and drug-likeness properties recommended accepted profiles of the majority of compounds. In conclusion, this work provides an extension of the chemical space of pyrazolopyrimidinone and pyrazolotriazolopyrimidinone chemotypes for the anti-inflammatory activity. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF